Levamisole (LVM) is a common adulterant in clandestinely manufactured cocaine (COC), with a range of well-documented deleterious health effects. Although the prevalence of LVM in COC has been widely noted, the subjective effects related to concomitant COC-LVM administration are poorly understood.
Aims:
The present study sought to compare the subjective effects of LVM alone and in combination with COC in male and female Sprague-Dawley rats trained to discriminate COC from vehicle injections.
Methods:
Male and female Sprague-Dawley rats were trained to discriminate COC from vehicle injections using a two-lever, food-reinforced drug discrimination procedure. Subsequent dose-effect curves were generated for COC, LVM, and a variety of COC-LVM combinations.
Results:
No significant difference in males and females was observed on any measure of responding. LVM alone dose-dependently decreased response rates and failed to produce substitution for COC. When LVM was administered with COC, previously ineffective doses of COC engendered COC-appropriate responding.
Conclusions:
LVM potentiates the subjective effects of COC when administered concomitantly. These findings are consistent with the popular notion that LVM is added as an adulterant to COC to amplify the subjective effects of COC administration.
AdamsJG (1978) Pharmacokinetics of levamisole. J Rheumatol Suppl4: 137–142.
2.
BaumanJLDiDomenicoRJ (2002) Cocaine-induced channelopathies: Emerging evidence on the multiple mechanisms of sudden death. J Cardiovasc Pharmacol Ther7: 195–202.
3.
BertolEMariFMiliaMGet al. (2011) Determination of aminorex in human urine samples by GC-MS after use of levamisole. J Pharm Biomed Anal55: 1186–1189.
4.
BoggianoMMCavigelliSADorseyJRet al. (2008) Effect of a cage divider permitting social stimuli on stress and food intake in rats. Physiol Behav95: 222–228.
5.
CarrollMEAnkerJJ (2010) Sex differences and ovarian hormones in animal models of drug dependence. Horm Behav58: 44–56.
6.
CasaleJFCorbeilEMHaysPA (2008) Identification of levamisole impurities found in illicit cocaine exhibits. Microgram J6: 82–89.
7.
ChiadmiFLyerACisterninoSet al. (2005) Stability of levamisole oral solutions prepared from tablets and powder. J Pharm Sci8: 322–325.
8.
ChitwoodDD (1985) Patterns and consequences of cocaine use. In: KozelNJAdamsEH (eds) Cocaine use in America: Epidemiologic and clinical perspectives. Rockville, MD: US Department of Health and Human Services, pp. 111–129.
9.
ColpaertFCNiemegeersCJEJanssenPAJ (1978) Factors regulating drug cue sensitivity. A long-term study on the cocaine cue. In: ColpaertFCRosecransJA (eds) Stimulus Properties of Drugs: Ten Years of Progress. Amsterdam: Elsevier/North-Holland Biomedical Press, pp. 281–299.
CraftRMKalivasPWStratmannJA (1996) Sex differences in discriminative stimulus effects of morphine in the rat. Behav Pharmacol7: 764–778.
12.
CraftRMStratmannJA (1996) Discriminative stimulus effects of cocaine in female versus male rats. Drug Alcohol Depend42: 27–37.
13.
de La GarzaRJohansonCE (1987) Discriminative stimulus properties of intragastrically administered d-amphetamine and pentobarbital in rhesus monkeys. J Pharmacol Exp Ther243: 955–962.
14.
DrenATJochimsenWGPlotnikoffNP (1971) Comparison of pemoline, cocaine, methamphetamine and methylphenidate self-administration in monkeys. Pharmacologist13: 281.
FischmanMWFoltinRW (1991) Utility of subjective-effects measurements in assessing abuse liability of drugs in humans. Br J Addict86: 1563–1570.
19.
GaltierPCocheYAlvinerieM (1983) Tissue distribution and elimination of [3H]levamisole in the rat after oral and intramuscular administration. Xenobiotica13: 407–413.
20.
GauvinDVBairdTJ (1999) Discriminative effects of compound drug stimuli: A focus on attention. Pharmacol Biochem Behav64: 229–235.
21.
GauvinDVBriscoeRJBairdTJet al. (1996) Selective attention to elements of a morphine stimulus: Idiosyncratic stimulus additivity of incidental cues. Exp Clin Psychopharmac4: 379–388.
22.
GauvinDVZimmermannZJ (2017) Conducting preclinical abuse liability screening in only one sex: Making a case for “reasonable exclusion.”Pharm Regul Aff6: 1–16.
23.
GlennonRAYoungR (2011) Drug discrimination: Practical considerations. In: GlennonRAYoungR (eds) Drug Discrimination: Applications to Medicinal Chemistry and Drug Studies. Hoboken, NJ: John Wiley & Sons, Inc., pp. 41–128.
24.
HessCRitkeNBroeckerSet al. (2014) Metabolism of levamisole and kinetics of levamisole and aminorex in urine by means of LC-QTOF-HRMS and LC-QqQ-MS. Anal Bioanal Chem405: 4077–4088.
25.
HofmaierTLufASeddikAet al. (2014) Aminorex, a metabolite of the cocaine adulterant levamisole, exerts amphetamine like actions at monoamine transporters. Neurochem Int73: 32–41.
KDIGO (2012) Chapter 3: Steroid-sensitive nephrotic syndrome in children. Kidney Int Suppl (2011)2: 163–171.
28.
KouassiECailléGLéryLet al. (1986) Novel assay and pharmacokinetics of levamisole and p-hydroxylevamisole in human plasma and urine. Biopharm Drug Dispos7: 71–89.
29.
LevandoskiMMPiketBChangJ (2003) The anthelmintic levamisole is an allosteric modulator of human neuronal nicotinic acetylcholine receptors. Eur J Pharmacol471: 9–20.
30.
LuyckxMRousseauFCazinMet al. (1982) Pharmacokinetics of levamisole in healthy subjects and cancer patients. Eur J Drug Metab Pharmacokinet7: 247–254.
31.
MartinRJRobertsonAP (2010) Control of nematode parasites with agents acting on neuro musculature systems: Lessons for neuropeptide ligand discovery. Adv Exp Med Biol692: 138–154.
32.
McCulloughLDde VriesGJMillerVMet al. (2014) NIH initiative to balance sex of animals in preclinical studies: Generative questions to guide policy, implementation, and metrics. Biol Sex Differ5: 15.
33.
MurrayJBAl-ShouraH (1976) Stability of cocaine hydrochloride in aqueous solution [proceedings]. J Pharm Pharmacol28 (Suppl): 24P.
34.
MutchRSHutsonPR (1991) Levamisole in the adjuvant treatment of colon cancer. Clin Pharm10: 95–109.
35.
National Research Council (2011) Guide for the Care and Use of Laboratory Animals. 8th ed.Washington, DC: National Academies Press.
36.
NegusSSBanksML (2011) Making the right choice: Lessons from drug discrimination for research on drug reinforcement and drug self-administration. In: GlennonRAYoungR (eds) Drug Discrimination: Applications to Medicinal Chemistry and Drug Studies. Hoboken, NJ: John Wiley & Sons, Inc., pp. 361–388.
37.
NowakLGRosayBCzégéDet al. (2015) Tetramisole and levamisole suppress neuronal activity independently from their inhibitory action on tissue non-specific alkaline phosphatase in mouse cortex. Subcell Biochem76: 239–281.
38.
OnuaguluchiGIgboINA (1990) Electrocardiographic changes induced by levamisole hydrochloride in the rat. Arch Int Pharmacodyn Ther305: 55–62.
39.
RobertsonAPBjornHEMartinRJ (1999) Resistance to levamisole resolved at the single channel level. FASEB J13: 749–760.
SpectorSMunjalISchmidtDE (1998) Effects of the immunostimulant, levamisole, on opiate withdrawal and levels of endogenous opiate alkaloids and monoamine neurotransmitters in rat brain. Neuropsychopharmacology19: 417–427.
42.
StadlerJRCaulWFBarrettRJ (2001) Effects of training dose on amphetamine drug discrimination: Dose-response functions and generalization to cocaine. Pharmacol Biochem Behav70: 381–386.
43.
StolermanIPChildsEFordMMet al. (2011) Role of training dose in drug discrimination: A review. Behav Pharmacol22: 15–29.
44.
SymoensJVeysEMielantsMet al. (1978) Adverse reactions to levamisole. Cancer Treat Rep62: 1721–1730.
45.
TallaridaCSEganEAlejoGDet al. (2014) Levamisole and cocaine synergism: A prevalent adulterant enhances cocaine’s action in vivo. Neuropharmacology79: 590–595.
46.
TallaridaCSTallaridaRJRawlsSM (2015) Levamisole enhances the rewarding and locomotor-activating effects of cocaine in rats. Drug Alcohol Depend149: 145–150.
47.
TallaridaRJ (2000) Drug Synergism and Dose-Effect Data Analysis. Boca Raton, FL: Chapman & Hall/CRC.
48.
TallaridaRJMurrayRB (1987) Manual of Pharmacologic Calculations with Computer Programs. 2nd ed.New York: Springer-Verlag.
49.
United Nations (1988) United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances. Available at: http://www.unodc.org/pdf/convention_1988_en.pdf (accessed 16 May 2018).
WilsonMCHitomiMSchusterCR (1969) Further studies of the self-administration of psychomotor stimulants in the rhesus monkey. In: Committee on Problems of Drug Dependence: Report of the Thirty-first meeting. Washington, DC: National Academy of Sciences – National Research Council, pp. 6057–6063.
52.
WoolvertonWL (2014) Analysis of drug interactions in behavioral pharmacology. In: ThompsonTDewsPBBarrettJE (eds) Advances in Behavioral Pharmacology: Volume 6: Neurobehavioral Pharmacology. New York: Psychology Press, pp. 275–302.
53.
WoolvertonWLMasseyBWWingerGet al. (1994) Evaluation of the abuse liability of aminorex. Drug Alcohol Depend36: 187–192.
54.
WoolvertonWLWangZVasterlingTet al. (2008) Self-administration of drug mixtures by monkeys: Combining drugs with comparable mechanisms of action. Psychopharmacology (Berl)196: 575–582.
55.
YoungRGlennonRA (1993) Cocaine-stimulus generalization to two new designer drugs: Methcathinone and 4-methylaminorex. Pharmacol Biochem Behav45: 229–231.
56.
ZimmermannZJGauvinDVPolingA (2017) Effects of levamisole on cocaine self- administration by rats. Psychol Rec67: 559–567.
